John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Harold S, Dienes K. The influence of ethnicity and nationality on cortisol reactivity to an acute laboratory stressor, with and without partner support. Poster presented at the American Psychosomatic Society 77th Annual Scientific Meeting; March 2019. Vancouver, Canada. [abstract] Psychosom Med. 2019 May; 81(4):A71. doi: 10.1097/PSY.0000000000000699
Basu N, Jones GT, Macfarlane GJ, Druce KL. Identification and validation of clinically relevant clusters of severe fatigue in rheumatoid arthritis. Psychosom Med. 2017 Nov;79(9):1051-8. doi: 10.1097/PSY.0000000000000498
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Pujol J, Fenoll R, Macia D, Martinez-Vilavella G, Alvarez-Pedrerol M, Rivas I, Forns J, Deus J, Blanco-Hinojo L, Querol X, Sunyer J. Airborne copper exposure in school environments associated with poorer motor performance and altered basal ganglia. Brain Behav. 2016 Apr 22;e00467. doi: 10.1002/brb3.467
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.